This document is page 96 of a Cannabis Investment Report published by Ackrell Capital in December 2017. It details legal developments regarding cannabis legalization and medical use in the United States and Canada, referencing specific legislation like the CSA and CDSA. The document contains a 'HOUSE_OVERSIGHT_024732' Bates stamp, indicating it was included in document production for a House Oversight Committee investigation, likely as part of a larger financial or investment portfolio review, though the text itself contains no direct references to Epstein or his associates.
| Name | Type | Context |
|---|---|---|
| Ackrell Capital, LLC |
Author of the Cannabis Investment Report
|
|
| United Nations |
Referenced regarding UN Conventions on controlled substances
|
|
| Health Canada |
Agency charged with administering Canada’s medical cannabis regulations
|
|
| Court of Appeal for Ontario |
Issued a 2000 decision ruling certain CDSA prohibitions unconstitutional
|
|
| FINRA |
Ackrell Capital is a member
|
|
| SIPC |
Ackrell Capital is a member
|
|
| House Oversight Committee |
Implied recipient of document via Bates stamp
|
| Location | Context |
|---|---|
"Despite marijuana and THC being Schedule I controlled substances under the CSA... 29 U.S. states and the District of Columbia have enacted medical cannabis laws"Source
"In a 2000 decision by the Court of Appeal for Ontario, the court held that certain criminal prohibitions under the CDSA related to cannabis were unconstitutional"Source
"The Marihuana [sic] Medical Access Regulations (MMAR), issued in 2001, permitted individuals... to grow their own cannabis plants for medical purposes"Source
Complete text extracted from the document (3,388 characters)
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document